Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH2616 Tablet in Subjects With Advanced Solid Tumors

NCT06329206 is registered in ClinicalTrials.gov with Suzhou Genhouse Bio Co., Ltd. as lead sponsor.

NCT NCT06329206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06329206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH2616 Tablet in Subjects With Advanced Solid Tumors
Lead sponsor
Suzhou Genhouse Bio Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 20, 2024
Completion date
September 1, 2026
Enrollment
156 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors